News
Enhanced Overall Survival in Metastatic NSCLC: Promising Results of TTFields Therapy in Phase III Lunar Trial
Oncologyme
/ Oct 08, 2023
FDA Grants Regular Approval to Pralsetinib for Adult Patients with Metastatic RET Fusion-Positive NSCLC
Oncologyme
/ Oct 04, 2023
Improved Clinical Outcomes in Advanced HER2-Negative Gastric or Gastroesophageal Junction Cancer Patients with Pembrolizumab and Chemotherapy: Keynote-859 Study Update in the protocol-specified PD-L1–selected populations.
Oncologyme
/ Sep 27, 2023
Phase III CHIPOR Trial: HIPEC Boosts Overall Survival and Peritoneal Progression-Free Survival in Women with First Platinum-Sensitive Relapse of Epithelial Ovarian Cancer
Oncologyme
/ Sep 26, 2023
Sotorasib Emerges as a Promising Treatment Option for Advanced NSCLC Patients with KRASG12C Mutation: Results from Phase 3 CODEBREAK 200 Trial
Oncologyme
/ Sep 21, 2023
Phase III CONTACT-03 trial: Atezolizumab Addition to Cabozantinib Fails to Improve Outcomes in Advanced Renal Cell Carcinoma Patients Post-Immune Checkpoint Inhibitor Therapy
Oncologyme
/ Sep 21, 2023
PHERGain: PET-based, pCR-adapted, chemotherapy-free HER2 dual blockade strategy shows substantial 3-year iDFS in HER2+ early breast cancer patients
Oncologyme
/ Sep 17, 2023
.png)
.png)